Tata India Pharma & Healthcare Fund
Ticker: mf13031
Decent
66/100
☆ Add to Watchlist
More Options
M
Mirae Asset Overnight Fund
The Mirae Asset Overnight Fund shows decent potential with stable growth and profitability metrics, but faces challenges in growth drivers and market sentiment.
View details
B
Bajaj Finserv Balanced Advantage Fund
Bajaj Finserv Balanced Advantage Fund shows potential for growth, but faces challenges in profitability and valuation metrics.
View details
A
Aditya Birla SL Income Plus Arbitrage Active FOF
The fund shows moderate potential but lacks strong growth drivers and technical momentum.
View details
T
Tata NIFTY 50 Index Fund
The Tata NIFTY 50 Index Fund presents a decent investment opportunity with stable growth potential, but investors should be cautious of market risks.
View details
D
DSP Natural Res & New Energy Fund
The fund shows potential in a growing sector, but faces challenges in execution and market conditions.
View details
F
Franklin India Dynamic Asset Allocation Active FOFs
The fund is positioned well in a future-ready sector with decent growth prospects, but it faces some execution risks and governance concerns.
View details
E
Edelweiss Large Cap Fund
The Edelweiss Large Cap Fund shows potential but faces challenges in growth consistency and valuation metrics. Investors should proceed with caution.
View details
B
Bajaj Finserv Small Cap Fund
Bajaj Finserv Small Cap Fund shows decent potential but comes with notable risks that need to be monitored.
View details
A
Axis Gold Fund
The Axis Gold Fund presents a risky investment opportunity with moderate growth potential but significant concerns regarding profitability and market sentiment.
View details
C
Canara Rob Value Fund
The fund shows decent potential but faces challenges in profitability and valuation metrics.
View details
I
ITI Multi-Cap Fund
While the ITI Multi-Cap Fund shows potential, it faces challenges in growth consistency and profitability metrics. Caution is advised for new investments.
View details
U
UTI Banking and Financial Services Fund
The UTI Banking and Financial Services Fund shows decent potential but faces challenges in profitability and valuation. Investors should be cautious and monitor market conditions closely.
View details
B
Bank of India Mid & Small Cap Equity & Debt Fund
The fund shows potential but is hindered by inconsistent growth and profitability metrics, making it a risky investment.
View details
B
Baroda BNP Paribas Small Cap Fund
The fund shows potential with a decent score, but investors should be cautious due to execution risks and market sentiment.
View details
B
Baroda BNP Paribas Flexi Cap Fund
The fund shows decent potential with consistent growth and profitability metrics, but caution is advised due to valuation concerns and execution risks.
View details
M
Motilal Oswal Liquid Fund
The Motilal Oswal Liquid Fund shows decent potential with stable growth and profitability metrics, though some risks remain.
View details
Business Overview
The Tata India Pharma & Healthcare Fund is a specialized mutual fund designed to capitalize on the growth potential of the Indian pharmaceutical and healthcare sectors. Ideal for investors seeking long-term capital appreciation, this fund focuses on companies that are at the forefront of innovation in healthcare. With a robust portfolio and experienced management, it aims to deliver consistent returns while mitigating risks associated with market volatility. This fund is crucial for those looking to invest in a sector that is essential to India's economic growth and public health.
- Targeted investment in pharma and healthcare sectors
- Long-term capital appreciation potential
- Managed by experienced professionals
- Focus on innovative and growth-oriented companies
- Mitigates risks associated with market fluctuations
Investment Thesis
Tata India Pharma & Healthcare Fund stands out due to its robust promoter credibility, significant growth potential in digital healthcare services, and attractive valuations compared to peers. This combination positions it as a compelling investment opportunity for retail investors seeking exposure in the booming healthcare sector.
- Strong backing from the Tata Group, ensuring trust and stability.
- Expanding digital services in healthcare, tapping into a growing market.
- Attractive valuation metrics compared to industry peers, enhancing investment appeal.
- Focus on innovative healthcare solutions aligns with current market trends.
- Potential for long-term growth driven by increasing healthcare demand.
Opportunity vs Risk
Opportunities
- Growing healthcare sector in India
- Increased demand for pharmaceuticals
- Government support for healthcare initiatives
- Rising health awareness among consumers
Risks ⚠️
- Regulatory changes impacting operations
- Intense competition in the market
- Price control on essential drugs
- Economic downturn affecting spending
📊 Stock Investment Checklist (100 Points)
Tata India Pharma & Healthcare Fund • Updated: 2025-09-29 15:50:43
-
10BusinessHighThe sector is poised for growth with increasing healthcare demands.
-
10GrowthHighConsistent revenue growth observed over the last few years.
-
10ProfitabilityHighROE and ROCE are above industry averages, but OCF is fluctuating.
-
8ValuationHighP/E and P/B ratios are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable with good liquidity ratios.
-
5GovernanceGoodPromoter holding is strong, but some pledging exists.
-
6DriversGoodStrong catalysts in the pipeline, but execution risks are present.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 66 / 100
• Decent
The Tata India Pharma & Healthcare Fund shows potential for growth, but investors should be cautious of valuation and execution risks.